Phase II evaluation of menogaril in patients with advanced hypernephroma

Harry J. Long, Mark D. Hauge, Terry M. Therneau, Jan C. Buckner, Stephen Frytak, Richard G. Hahn

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)261-262
Number of pages2
JournalInvestigational New Drugs
Issue number3
StatePublished - Aug 1991


  • hypernephroma
  • menogaril
  • phase II
  • renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II evaluation of menogaril in patients with advanced hypernephroma'. Together they form a unique fingerprint.

Cite this